EUCTR2011-005115-82-LT进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients with Active, Mild or Moderate Ulcerative Colitis not Adequately Controlled on a Background Oral 5-ASA Regimen
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with diagnosed UC fulfilling the following criteria at Screening are eligible for participation in the study:
- •1. Age 18 to 75 years, inclusive
- •2. Established diagnosis of UC, based on clinical history, exclusion of infectious causes (e.g., enteric bacterial infection, Clostridium difficile, parasites, ova, etc.), characteristic endoscopic findings, and histopathology results from biopsies.
- •3. UC of mild or moderate severity with an Ulcerative Colitis Disease Activity Index (UCDAI) score = 4 and = 10 according to Sutherland, with a mucosal appearance subscore of = 1 and a physician’s rating of disease activity of 1 or 2.
- •4. Currently experiencing active UC (flare) despite taking a therapeutic dose of an oral 5-ASA (e.g., mesalamine = 2.4 g/day, or equivalent dose of another 5-ASA for a minimum of 6 weeks prior to randomization. At screening, photographic evidence of active UC based on mucosal appearance must be obtained from the flexible sigmoidoscopy procedure.
- •5. Women of childbearing potential, or men of reproductive potential, must be willing to use an acceptable form of contraception. Acceptable forms of contraception are defined as those with a failure rate < 1% when properly applied and include: a combination oral pill, some intra-uterine devices, and a sterilized partner in a stable relationship. Female patients must not be actively breast-feeding through the entire study period.
- •6. Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and also able to comply with all requirements of the study. Must be able to understand and voluntarily sign a written informed consent prior to any study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Patients who meet any of the following criteria at Screening are to be excluded from study participation:
- •1. Patients with limited distal proctitis (from anal verge up to 15 cm above the pectineal line).
- •2. Patients with severe UC (UCDAI > 10 or PGA > 2), or patients not currently in an active phase or flare (defined in this study as a UCDAI score < 4).
- •3. Patients with infectious colitis (based on positive microbiologic tests, Clostridium difficile toxin, or ova and parasites per the central laboratory) or any recent history of infectious colitis (within 30 days of Screening).
- •4. Patients with a history of active malignancy or carcinoma in situ within the last 5 years (excised or treated non-melanoma skin cancers are not exclusionary).
- •5. Patients with an active ulcer or bleeding disorder that may affect evaluation of blood in the stool.
- •6. Evidence or history of toxic megacolon or bowel resection.
- •7. Patients with Crohn’s disease or indeterminate colitis.
- •8. Patients with a known hypersensitivity to budesonide or any of the ingredients of the budesonide MMX tablets
- •9. Patients with active tuberculosis or any other active systemic or local bacterial, fungal, or viral infection.
- •10. Patients with liver cirrhosis, evident hepatic or renal disease or insufficiency, or significant impairment of the biohumoral parameters (= 2.5 x upper limit of normal [ULN] for ALT, AST, GGT, or = 2 x ULN for creatinine). Elevations in bilirubin due to benign conditions such as Gilbert’s syndrome are not exclusionary.
- •11. Patients with severe diseases in other organs or systems.
- •12. Patients with local or systemic complications or other pathological states requiring therapy with corticosteroids and/or immunosuppressive agents.
- •13. Patients diagnosed with type 1 diabetes.
- •14.Patients diagnosed as having glaucoma, or with a family history of glaucoma in first degree relatives.
- •15. Patients with known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV), according to the local privacy policy.
- •16. Patients with severe anemia (< 9 g/dL hemoglobin), leukopenia (< 2.5 x 109 white blood cells [WBC]/L), or granulocytopenia (< 1.2 x 109 cells/L).
- •17. Patients with a history of pancolitis (disease that extends to the hepatic flexure or beyond) for = 8 years or left-sided colitis (disease confined to the left colon [i.e., distal to the splenic flexure]) = 15 years who have not yet completed a surveillance colonoscopy for dysplasia/colorectal cancer screening within the past year.
- •18. Prior treatment with budesonide MMX.
- •19. Use of oral corticosteroids including other budesonide formulations within the last 4 weeks prior to randomization.
- •20. Use of any rectal 5-ASA or corticosteroid formulations within the last 2 weeks prior to randomization.
- •21. Use of immunosuppressive agents within the last 8 weeks prior to randomization.
- •22. Use of anti-tumor necrosis factor-alpha (anti-TNFa) agents or other biologic therapies within the last 3 months prior to randomization.
- •23. Participation in experimental therapeutic studies within the last 30 days prior to randomization (or within the last 3 months if in an anti-TNFa or biologic agent study). Note: patients who participated in observational-only studies (and who did not receive study therapy) are not excluded.
- •24. Any other medical condition that in the Principal Investigator’s opinion would make the administration of the study drug or study procedures hazardous to the patient, or obscure the
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-HURegeneron Pharmaceuticals, Inc.803
进行中（未招募）
1 期
A clinical trial to assess the efficacy and safety of Nemolizumab (CD14152) compared to placebo in patients with Atopic Dermatitis.MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2019-001888-75-BEGalderma S.A.750
进行中（未招募）
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-001903-60-NOSanofi-aventis recherche & développement500
进行中（未招募）
1 期
A Study to Evaluate ESK-001 in Patients with PsoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2022-002633-34-CZAlumis Inc.210
进行中（未招募）
1 期
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003158-18-ITBIOGEN IDEC RESEARCH LIMITED106